Clinical and Molecular Hepatology

Papers
(The TQCC of Clinical and Molecular Hepatology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis307
Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma205
Reply to correspondence on “Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis”176
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial161
Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues160
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”116
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China74
Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”66
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”64
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”64
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”57
Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”56
Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”53
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy50
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus45
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”44
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”44
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”43
Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis42
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments41
Unveiling the Intratumor Microbiome in Liver Cancer: Current Insights and Prospective Applications39
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation36
The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus35
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future34
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer33
Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances32
Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”32
Surveillance for hepatocellular carcinoma: It is time to move forward32
Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research32
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations31
Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”30
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study29
Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization29
Another oral antiviral treatment, but still far away from hepatitis B virus cure29
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?28
Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods28
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma27
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease26
Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”26
Approaches to quantifying hepatitis B virus covalently closed circular DNA26
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma26
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations25
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise25
Can hepatocellular carcinoma recurrence be prevented after liver transplantation?24
Nucleos(t)ide analog therapy of chronic hepatitis B and extrahepatic cancer risk: Is tenofovir better than entecavir?: Editorial on “Extrahepatic malignancies and antiviral drugs for chronic hepatitis23
Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with earl23
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign23
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD23
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antiv22
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with 22
Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease p22
Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”22
Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”22
Correspondence to editorial on “Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis”22
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”22
Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepati21
Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis21
Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK21
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systemati21
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment20
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis20
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review19
Screening strategy for non-alcoholic fatty liver disease19
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound19
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?19
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications19
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management18
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?18
The role of the hepatic autonomic nervous system18
Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease18
A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective16
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology16
Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes16
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?16
Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection16
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers15
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus15
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity15
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity15
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hep15
Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study15
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases14
Microbiome and metabolomics in alcoholic liver disease14
Vibration-Controlled Transient Elastography in Shaping the Epidemiology and Management of Steatotic Liver Disease14
Current status and outcome of liver transplantation in South Korea14
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”14
Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognos- tic factor in hepatitis C virus-related hepatocellular carcinoma14
MARC1 downregulation reduces hepatocyte lipid content by increasing beta-oxidation14
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults14
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals14
Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”14
KASL clinical practice guidelines for management of autoimmune hepatitis 202213
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective13
Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive13
Changes in the epidemiology and management of bacterial infections in cirrhosis13
Prospect of emerging treatments for HBV functional cure13
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma13
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection13
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study13
Adding to the confusion in more than just the name13
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma13
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls13
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future12
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region12
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials12
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B12
Anti-fibrotic treatments for chronic liver diseases: The present and the future12
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease12
Preface12
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis12
Liquid Biopsy in Hepatocellular Carcinoma: Challenges, Advances, and Clinical Implications11
KASL clinical practice guidelines for management of chronic hepatitis B11
Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”11
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial11
Erratum to ‘Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”’ [Clin Mol Hepatol 2023;29:1048-1049]11
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?10
Toward hepatitis C virus elimination using artificial intelligence10
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)10
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases10
JCAD, a new potential therapeutic target in cholestatic liver disease10
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact10
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective10
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply10
Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis9
Congratulatory remarks9
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study9
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma9
Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis9
An analysis of polygenic risk scores for non-alcoholic fatty liver disease8
Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”7
HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?7
Evidence-based hyponatremia management in liver disease7
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”7
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”7
MAFLD: How is it different from NAFLD?7
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B7
Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease7
COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis7
Acute on chronic liver failure in cirrhosis7
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”7
Letter regarding “Evidence-based hyponatremia management in liver disease”7
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future7
Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”7
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey7
0.23650503158569